@article {de Jonghe602作者= {Adriaan d . de Jongh和鲁本P.A. van Eijk和莱昂哈德·a·汤米·m·缩聚和安妮塔Beelen他科妮van der Meijden和迈克尔·a·范Es Johanna硕士Visser-Meily和以斯帖t . Kruitwagen Jan h . Veldink和伦纳德h . van den Berg}, title ={发展Rasch-Built肌萎缩性脊髓侧索硬化症损害多畴的规模来衡量疾病进展在ALS},体积={101}={6},页面= {e602——e612} = {2023}, doi = {10.1212 / WNL。出版商0000000000207483}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={背景和目标当前尺度用于肌萎缩性脊髓侧索硬化症(ALS)试图总结不同的功能域或{首页\ textquotedblright} {\ textquotedblleft}维度1总分,可能不能准确地描述个别病人{\ textquoteright}年代疾病严重程度和预后。总分的使用风险声明治疗无效如果不是所有维度ALS疾病进展同样的影响。我们旨在开发ALS障碍多畴的规模(目标),全面描述疾病进展和增加的可能性识别有效的治疗方法。方法修改后的ALS功能评定量表(ALSFRS-R)和初步的问卷调查,基于文献综述和病人输入,完成在线从荷兰ALS患者注册中心每隔两月一次的在一段时间内的12个月。拉希两周两次试验法的因素分析,分析,和信噪比进行了优化策略来创建一个多畴的规模。可靠性、纵向下降和对生存进行评估。所需的样本量检测35 \ %降低发展速度超过6或12个月评估临床试验,定义了ALSFRS-R或目标分量表作为主要终点的家庭。结果初步调查问卷,包括110个问题,完成了367个病人。三个一维的分量表,和多畴的规模是由7球,11个马达,和5呼吸问题。分量表实现拉希模型需求,与优秀的0.91 {\ textendash} 0.94两次试验法的可靠性和强大与生存的关系(p < 0.001)。与ALSFRS-R相比,信噪比高,患者拒绝每内部氧化物更均匀。 Consequently, the estimated sample size reductions achieved with the AIMS compared with those achieved with the ALSFRS-R were 16.3\% and 25.9\% for 6-month and 12-month clinical trials, respectively.Discussion We developed the AIMS, consisting of unidimensional bulbar, motor, and respiratory subscales, which may characterize disease severity better than a total score. AIMS subscales have high test-retest reliability, are optimized to measure disease progression, and are strongly related to survival time. The AIMS can be easily administered and may increase the likelihood of identifying effective treatments in ALS clinical trials.AIMS=ALS Impairment Multidomain Scale; ALS=amyotrophic lateral sclerosis; ALSFRS-R=Revised ALS Functional Rating Scale; ICC=intraclass coefficient; RMSEA=root mean square error of approximation; ROADS=Rasch-Built Overall ALS Disability Scale}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/101/6/e602}, eprint = {//www.ez-admanager.com/content/101/6/e602.full.pdf}, journal = {Neurology} }